Alto Group Holdings ALTO 深 沪
已收盘 08-01 16:00:00 美东时间
1.05
+0.040
+3.96%
华盛通- 最 高1.10
- 今 开1.01
- 成交量 37.70万股
- 最 低 0.97
- 昨 收 1.01
- 总市值 8107.17万
- 52周最高 2.05
- 市盈率 静 --
- 换手率 0.49%
- 52周最低 0.76
- 委 比 -86.76%
- 总股本 7721.11万
- 历史最高 23.969
- 量 比 2.09
- 振 幅 12.87%
- 历史最低 0.22
- 每 手 1
- 风险率 0.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Hesai's JT Series 3D Lidar Revolutionizes the Future of Autonomous Farming
PALO ALTO, Calif., July 30, 2025 /PRNewswire/ -- Hesai Technology (Nasdaq: HSAI), a global leader in lidar solutions, announces today that it will supply its advanced JT series lidar sensors...
07-30 20:30
Alto Ingredients, Inc. to Release Second Quarter 2025 Financial Results on August 6, 2025
Alto Ingredients, Inc. (NASDAQ: ALTO) announced the release of its Q2 2025 financial results after market close on August 6, 2025. Management will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET, featuring webcast remarks and a Q&A session. Participants can join via webcast at Alto Ingredients' website, register for an access code, or dial-in using the provided numbers. The webcast will be archived for one year, and a telephonic replay will...
07-30 12:30
Palo Alto Networks Completes Acquisition of Protect AI
Extends AI security leadership with comprehensive protection for the entire AI lifecycle SANTA CLARA, Calif., July 22, 2025 /PRNewswire/ -- Palo Alto Networks® (NASDAQ: PANW), the global cyb...
07-22 21:15
Alto Ingredients, Inc. Names Gilbert Nathan Chair, Dianne Nury Vice-Chair and Elects Two New Directors
<p>Alto Ingredients, Inc. announced new board members Gilbert Nathan as Chair, Dianne Nury as Vice-Chair, Alan R. Tank, and Jeremy T. Bezdek. Nathan emphasized the importance of strategic initiatives to enhance shareholder value. CEO Bryon McGregor highlighted Tank's expertise in renewable energy, particularly decarbonization, and Bezdek's experience in capital raising and operational excellence. Both new directors bring decades of industry exper...
06-26 20:05
Alto Neuroscience Identifies EEG Biomarker And Reports Pharmacodynamic Results From Phase 2 Trial Of ALTO-203 For Major Depressive Disorder
Demonstrated target engagement and response prediction for ALTO-203 by theta/beta ratio, a commonly used EEG index of cortical arousal and attentional control ALTO-203, a non-stimulant compound which demonstrated
06-26 19:37
Alto Buys Depression and Parkinson's Drug Portfolio for $1.75M Upfront, With $71.5M in Future Milestones
Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that it entered into an
06-03 18:05
Alto Ingredients Faces Nasdaq Delisting Notice
Alto Ingredients ( ($ALTO) ) has provided an update. On May 19, 2025, Alto Ingr...
05-24 05:03
Bridgebio Pharma Publishes Data Showing Sustained Increase In Serum TTR Levels Predicted Improved Survival In ATTRibute-CM, Phase 3 Trial Of ATTR-CM
- For each 5-mg/dL increase in serum TTR level within 28 days of starting treatment, the relative risk reduction of mortality was up to 31.6% through Month 30, confirming the hypothesis that ever better levels of
05-20 00:37
Broadcom Announces Third-Generation Co-Packaged Optics (CPO) Technology With 200G/lane Capability
Key partner milestones with CPO switches demonstrate ecosystem readiness for ne...
05-15 21:00
